All news articles for November 2012

Neptune and Aker facing off in court yet again

Krill wars

Neptune and Aker facing off in court yet again

By RJ Whitehead

Australia is the site of the latest battle between Neptune and Aker Biomarine. In addition to patent strife between the two krill majors in American courts, Canadian Neptune has now announced that it filed opposition to an Aker patent application earlier...

Flaxseed shows blood pressure-lowering potential: Study

Flaxseed shows blood pressure-lowering potential: Study

By Stephen Daniells

Daily consumption of flaxseed-fortified bakery products may reduce blood pressure levels in patients with peripheral arterial disease (PAD), suggests new data presented at the November American Heart Association 2012 Scientific Sessions.

USANA chooses science over speed, official says

USANA chooses science over speed, official says

By Hank Schultz

USANA Health Sciences has taken a conservative approach to new product development, making it a company lean on products but long on trust, says Brian Dixon, PhD, executive director of new product development.

Evolva will reduce the cost of its new yeast-derived resveratrol, it says

Evolva pays €550,000 for Fluxome resveratrol business

By Shane Starling

Swiss biotech firm Evolva has bought failing Fluxome’s, yeast-derived resveratrol business for about €550,000 in cash and shares, but says it has no interest in the remaining omega-3 business being sold by sealed auction.

Senators Durbin and Blumenthal want to put the energy drinks industry firmly inside its box...

Senators tilt at Red Bull as FDA hints at energy action

By Ben Bouckley

The Food and Drug Administration (FDA) has told US Senators Dick Durbin and Richard Blumenthal that is reviewing the safety of energy drinks and may take regulatory action if it finds a health risk.

Challenge models hold promise for probiotic claim substantiation

New models hold promise for probiotic claim substantiation

By Nathan GRAY

Exposing healthy people to modified pathogens in a controlled clinical trial setting could be an exciting new way for industry to overcome the challenges of health claim substantiation, says Nizo Food Research expert.

Follow us

Products

View more

Webinars